\
&
Contact us
\
&
Contact us
Published on | 4 years ago
ProgrammesThe knowledge and innovation community on raw materals (EIT raw materials) has published its call for proposals for projects to start in 2023. This year, for the first time, EIT Raw Materials has expanded this call to non-members. Everybody is encouraged to submit new project proposals that will generate a significant impact on European industrial competitiveness, innovation capacity and human capital, as well as empower students and entrepreneurs driving towards the circular economy, the digital transition and the contribution towards the EU Green Deal goals.
The procedure is in two stages to make sure initial ideas can be adapted and be more refined before the final submission date. The draft proposal and the expression of interest should therefore be submitted by the 31st of May 2022 and the final submission date is the 14th of September 2022. All documents and explanation of the call can be found here.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
